Nanoantibodies or "nAb" are single-domain VHH antibodies derived from camelidae (camels, llamas, alpacas, etc.). Compared with conventional monoclonal and polyclonal antibodies, nAbs have the following advantages:

Small size (~15kd)
High affinity (frequently nanomolar range)
High specificity
Unsurpassed stability

Market Analysis and Insights: Global Nano Antibodies Market
The global Nano Antibodies market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Nano Antibodies market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Nano Antibodies market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Nano Antibodies market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Nano Antibodies market.

Global Nano Antibodies Scope and Market Size
Nano Antibodies market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Nano Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Monovalent Nanobody
Multivalent and multispecific Nanobodies
Fusion Nanobody

Segment by Application
Disease detection in vitro
Non-invasive diagnosis in vivo
Tumor targeted therapy
Nervous system disease
Circulatory disease
Infectious disease
Other

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Ablynx
PREGENE
Alphamab
PersonGen